Farnoush Abar
Hematology & Oncology · Seattle, WANPI 1558560342
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,950 of the $19,892 with a category attached, or 80.2%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 96.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $19,738 and has fallen 99.9% since, to $20 in 2024.
Across 52 payments — averaging $382.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- Johnson & Johnson$307
- Amgen$48
- Novartis$44
- Genentech USA, Inc.$34
- Merck$32
- plus $239 from 13 others
Across 33 payments — averaging $4846.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$160K
What the payments were for
- Speaking & faculty fees$15,95080%
- Travel & lodging$2,76414%
- Food & beverage$1,1276%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $19,188 |
| Johnson & Johnson | 14 | $307 |
| Amgen | 2 | $48 |
| Novartis | 2 | $44 |
| Genentech USA, Inc. | 2 | $34 |
| Merck | 2 | $32 |
| Seagen Inc. | 2 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| AbbVie | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$18,937
How this compares
$19,892 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 19 | $274,237 |
| BrukinsaZanubrutinib | 15 | $218,183 |
| VerzenioAbemaciclib | 14 | $213,860 |
| EliquisApixaban | 36 | $30,943 |
| Abiraterone Acetate | 22 | $20,324 |
| Imatinib Mesylate | 23 | $12,548 |
| Acyclovir | 47 | $615 |
| Letrozole | 36 | $501 |
| Oxycodone Hcl | 35 | $474 |
| Tamoxifen Citrate | 23 | $450 |
| Olanzapine | 18 | $406 |
| Dexamethasone | 31 | $343 |
| Hydroxyurea | 18 | $328 |
| Prednisone | 45 | $304 |
| Anastrozole | 11 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $17 | $214,26632 claims |
| PfizerEliquis | $21 | $30,94336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.